Financial Sense Advisors Inc. Has $2.98 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Financial Sense Advisors Inc. decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 6.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,428 shares of the medical research company’s stock after selling 779 shares during the period. Amgen makes up about 1.0% of Financial Sense Advisors Inc.’s investment portfolio, making the stock its 26th largest holding. Financial Sense Advisors Inc.’s holdings in Amgen were worth $2,979,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Capital Performance Advisors LLP bought a new stake in shares of Amgen in the third quarter worth $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the 3rd quarter worth approximately $29,000. Heck Capital Advisors LLC bought a new stake in shares of Amgen during the 4th quarter worth approximately $36,000. Kennebec Savings Bank acquired a new stake in shares of Amgen in the 3rd quarter valued at approximately $57,000. Finally, PrairieView Partners LLC lifted its stake in Amgen by 118.3% in the fourth quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 97 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 0.5 %

Shares of AMGN stock opened at $294.27 on Thursday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a 50 day moving average of $275.15 and a 200-day moving average of $300.77. The firm has a market cap of $158.18 billion, a P/E ratio of 38.98, a PEG ratio of 2.53 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Sell-side analysts anticipate that Amgen Inc. will post 20.6 earnings per share for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.24%. Amgen’s payout ratio is 126.09%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AMGN. Piper Sandler lifted their target price on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Leerink Partners cut their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft reduced their target price on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Wells Fargo & Company lowered their target price on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a report on Friday, January 10th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $314.09.

Insiders Place Their Bets

In related news, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Murdo Gordon sold 8,771 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the transaction, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,405 shares of company stock worth $10,410,596 in the last quarter. 0.69% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.